SCHEMBL6900354

SCHEMBL6900354

Nc1ncnc2c1ncn2[C@@H]1O[C@H](C(O)SCCC(=O)O)C(O)C1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 5/20 0.60
HIF1A Q16665 1/20 0.60
TMEM97 Q5BJF2 1/20 0.60
SIGMAR1 Q99720 1/20 0.60
DOT1L Q8TEK3 3/20 0.58
EHMT2 Q96KQ7 3/20 0.58
CARM1 Q86X55 2/20 0.58
KMT2A Q03164 2/20 0.58
NNMT P40261 2/20 0.58
TRDMT1 O14717 1/20 0.58
PRMT5 O14744 1/20 0.58
SUV39H1 O43463 1/20 0.58
PRMT3 O60678 1/20 0.58
INMT O95050 1/20 0.58
NSD2 O96028 1/20 0.58
PNMT P11086 1/20 0.58
DNMT1 P26358 1/20 0.58
HNMT P50135 1/20 0.58
WDR5 P61964 1/20 0.58
SETDB1 Q15047 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6900339 1.00 AHCY (0.60) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL2118345 0.85 AHCY (0.61) AHCYDOT1LKMT2APRMT5WDR77
SCHEMBL14696726 0.84 PRKACA (0.61) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL4191285 0.83 AHCY (0.59) AHCYDOT1LKMT2APRMT5WDR77
SCHEMBL14696483 0.83 PRKACA (0.65) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL14696395 0.83 PRKACA (0.65) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL101380 0.82 AHCY (0.62) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL29385449 0.82 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL2117335 0.82 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1DOT1L
SCHEMBL1757011 0.82 AHCY (0.68) AHCYHIF1ATMEM97SIGMAR1DOT1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482977-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed
WO-2003074083-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP AHCY 62/4885HIF1A 3905/4885TMEM97 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.